Kenneth McClure, MD
Internal Medicine · Longview, TXNPI 1770550311
Payments from drug & device makers
Across 133 payments — averaging $16.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$658
- AbbVie$261
- GSK$200
- AstraZeneca$134
- Amgen$98
- Lilly USA, LLC$85
- plus $711 from 24 others
What the payments were for
- Food & beverage$2,12299%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $658 |
| AbbVie | 15 | $261 |
| GSK | 12 | $200 |
| AstraZeneca | 6 | $134 |
| Amgen | 6 | $98 |
| Lilly USA, LLC | 6 | $85 |
| Pfizer | 4 | $64 |
| Axsome Therapeutics, Inc. | 2 | $63 |
| Johnson & Johnson | 4 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Avanir Pharmaceuticals, Inc. | 3 | $43 |
| Bayer | 2 | $42 |
| Amarin Pharma, Inc. | 3 | $42 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $32 |
| Novartis | 2 | $28 |
| Merck | 2 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Cequr Corporation | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Abiomed | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| GE HealthCare | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$2,147 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 416 | $179,559 |
| OzempicSemaglutide | 101 | $120,398 |
| JardianceEmpagliflozin | 122 | $72,059 |
| JanuviaSitagliptin Phosphate | 112 | $64,075 |
| NuplazidPimavanserin Tartrate | 26 | $63,746 |
| MounjaroTirzepatide | 54 | $56,367 |
| XareltoRivaroxaban | 80 | $43,919 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $40,002 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 37 | $29,540 |
| TradjentaLinagliptin | 28 | $26,347 |
| MyrbetriqMirabegron | 76 | $25,442 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $20,779 |
| TrulicityDulaglutide | 12 | $19,423 |
| EntrestoSacubitril/Valsartan | 53 | $19,375 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $179,559416 claims |
| Novo NordiskOzempic | $658 | $120,398101 claims |
| MerckJanuvia, Janumet Xr, Janumet, Belsomra | $25 | $115,450186 claims |
| Boehringer IngelheimJardiance, Tradjenta | $25 | $98,406150 claims |
| Lilly USA, LLCMounjaro, Trulicity | $85 | $75,79066 claims |
| Acadia Pharmaceuticals IncNuplazid | $23 | $63,74626 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $200 | $46,51957 claims |
| Johnson & JohnsonXarelto | $56 | $43,91980 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Farxiga | $134 | $28,62660 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $25,44276 claims |
| NovartisEntresto | $28 | $19,37553 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $43 | $16,63122 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Longview
- Kathleen HarrisLongview$3.1M
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.